Nurix Therapeutics initiated a Phase 3 trial for its cancer drug bexobrutideg in relapsed/refractory CLL/SLL and expanded its oncology and immunology pipeline in Q3 2026. The company earned $27 million from collaborations with Gilead, Pfizer, and Sanofi, including a $10 million milestone from Sanofi. Following a $700 million upfront payment from Roche, Nurix holds $1.1 billion in cash and securities, supporting operations into late 2029. Net income for Q3 2026 surged to $549.8 million, driven by license revenue from the Roche collaboration, marking a significant financial and clinical milestone for Nurix.
Sanofi SA, a key collaborator with Nurix Therapeutics, holds a market cap of $96.07 billion and offers a dividend yield of 6.04% on Pluang as of Oct 13, 2026 03:02 WIB. Gilead Sciences, another partner, trades with a market cap of $187.44 billion and a dividend yield of 2.17%, with most Pluang users selling their positions. Sanofi's stock price is $39.74, down 0.82% in the last day, while Gilead's price is $150.35, down 0.54%. This market activity provides context to Nurix's collaborations and financial updates.
